216 related articles for article (PubMed ID: 30941644)
1. Association of FOXA1 and EMT markers (Twist1 and E-cadherin) in breast cancer.
BenAyed-Guerfali D; Dabbèche-Bouricha E; Ayadi W; Trifa F; Charfi S; Khabir A; Sellami-Boudawara T; Mokdad-Gargouri R
Mol Biol Rep; 2019 Jun; 46(3):3247-3255. PubMed ID: 30941644
[TBL] [Abstract][Full Text] [Related]
2. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression.
Xu Y; Qin L; Sun T; Wu H; He T; Yang Z; Mo Q; Liao L; Xu J
Oncogene; 2017 Feb; 36(8):1157-1166. PubMed ID: 27524420
[TBL] [Abstract][Full Text] [Related]
3. FOXA1 Expression in Nasopharyngeal Carcinoma: Association with Clinicopathological Characteristics and EMT Markers.
Ammous-Boukhris N; Ayadi W; Derbel M; Allaya-Jaafar N; Charfi S; Daoud J; Sellami-Boudawara T; Mokdad-Gargouri R
Biomed Res Int; 2020; 2020():4234632. PubMed ID: 32685483
[TBL] [Abstract][Full Text] [Related]
4. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
5. Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients.
van Nes JG; de Kruijf EM; Putter H; Faratian D; Munro A; Campbell F; Smit VT; Liefers GJ; Kuppen PJ; van de Velde CJ; Bartlett JM
Breast Cancer Res Treat; 2012 May; 133(1):49-59. PubMed ID: 21796367
[TBL] [Abstract][Full Text] [Related]
6. Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation.
Zhang YQ; Wei XL; Liang YK; Chen WL; Zhang F; Bai JW; Qiu SQ; Du CW; Huang WH; Zhang GJ
PLoS One; 2015; 10(8):e0135851. PubMed ID: 26295469
[TBL] [Abstract][Full Text] [Related]
7. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
[TBL] [Abstract][Full Text] [Related]
8. High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.
Riaz M; Sieuwerts AM; Look MP; Timmermans MA; Smid M; Foekens JA; Martens JW
Breast Cancer Res; 2012 Sep; 14(5):R123. PubMed ID: 22967435
[TBL] [Abstract][Full Text] [Related]
9. Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer.
Jing X; Liang H; Hao C; Hongxia L; Cui X
Aging (Albany NY); 2019 Sep; 11(18):7442-7456. PubMed ID: 31562808
[TBL] [Abstract][Full Text] [Related]
10. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
11. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
12. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
[TBL] [Abstract][Full Text] [Related]
13. FOXA1 Induces E-Cadherin Expression at the Protein Level via Suppression of Slug in Epithelial Breast Cancer Cells.
Anzai E; Hirata K; Shibazaki M; Yamada C; Morii M; Honda T; Yamaguchi N; Yamaguchi N
Biol Pharm Bull; 2017; 40(9):1483-1489. PubMed ID: 28867731
[TBL] [Abstract][Full Text] [Related]
14. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.
Thorat MA; Marchio C; Morimiya A; Savage K; Nakshatri H; Reis-Filho JS; Badve S
J Clin Pathol; 2008 Mar; 61(3):327-32. PubMed ID: 18037662
[TBL] [Abstract][Full Text] [Related]
15. PGC1α Cooperates with FOXA1 to Regulate Epithelial Mesenchymal Transition through the TCF4-TWIST1.
Fang XQ; Lee M; Lim WJ; Lee S; Lim CH; Lim JH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897813
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
17. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
De Lara S; Nyqvist J; Werner Rönnerman E; Helou K; Kenne Sarenmalm E; Einbeigi Z; Karlsson P; Parris TZ; Kovács A
BMC Cancer; 2019 Feb; 19(1):187. PubMed ID: 30819139
[TBL] [Abstract][Full Text] [Related]
18. High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer.
Horimoto Y; Sasahara N; Sasaki R; Hlaing MT; Sakaguchi A; Saeki H; Arakawa A; Himuro T; Saito M
Breast Cancer Res Treat; 2020 Aug; 183(1):41-48. PubMed ID: 32572714
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
20. FOXA1 is an independent prognostic marker for ER-positive breast cancer.
Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S
Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
